Page 2472 - Williams Hematology ( PDFDrive )

2443
2442 Index Index 2443

special problems associated with, 2130 endothelium, 1968–1969, 1968f, 1968t, etiology and pathogenesis, 398,
therapy, 2121–2124 1969f, 1970f 2026–2028, 2026f, 2026t, 2027f
antifibrinolytic agents, 2123, 2317t, 2318 fibrinolysis, 1972–1975, 1973f, 1974t, hemodialysis and, 2032
desmopressin, 2122–2123 1975f heparin reexposure following, 2032
factor VIII replacement therapy, inhibition of platelet activation and laboratory features, 2029–2030, 2030t
2121–2122, 2121t, 2122t recruitment, 1971, 1972f in pregnancy, 2032, 2277
fibrin glue, 2123 molecular changes in inflammation, treatment
gene therapy, 441–442, 2129–2130 1976–1979, 1977t, 1979t danaparoid, 398, 2030
home therapy, 2124 nitric oxide, 1970–1971 duration, 2032
liver transplantation, 2129 protein C pathway, 1971–1972 fondaparinux, 399, 2030
of major nonsurgical hemorrhage, 2123 HEMPAS (hereditary erythroblastic nonheparin anticoagulants, 2030–2031,
of minor/moderate hemorrhage, 2123 multinuclearity with a positive 2031t
prophylactic, 2124 acidified serum test), 567, 2340 plasma exchange, 429t
for surgical procedures, 2123–2124 Henoch-Schönlein purpura (HSP), 1162, platelet transfusion, 2032
Hemophilia B (factor IX deficiency, 2103–2104, 2104f warfarin, 396, 2031–2032
Christmas factor deficiency), 1985, Heparan sulfate, 62, 267 Hepatic artery thrombosis (HAT), 2195
2126–2130 Heparin, 397–398. See also Low-molecular- Hepatic disease/dysfunction
clinical features, 1988, 2128–2129 weight heparin (LMWH) acanthocytosis in, 680–681
course and prognosis, 2129 administration and monitoring, 397 in acute fatty liver of pregnancy, 2012,
differential diagnosis, 2128 adverse effects, 397–398, 2099–2100, 2211
etiology and pathogenesis, 1922, 2126 2277. See also Heparin-induced in AL amyloidosis, 1779, 1781–1782
factor IX inhibitor in, 2129 thrombocytopenia (HIT) in antiphospholipid syndrome, 2240
gene therapy, 441–442, 2129–2130 for antiphospholipid syndrome, 2244, 2245 bleeding in, 2193
genetics and molecular biology, 441, antithrombin and, 2202 chronic, 636
2126–2127, 2127f binding to von Willebrand factor, 2168 in disseminated intravascular coagulation,
laboratory features, 2128 choice of, 398 2204, 2204t, 2205t
pregnancy and, 121 for disseminated intravascular coagulation, disseminated intravascular coagulation
prenatal diagnosis and carrier detection, 2213–2214 and, 2208
121, 2127 during fibrinogen replacement therapy, dose modification in patients with, 316t
special problems associated with, 2130 2157 drug-related, 1410
therapy, 2128–2129, 2128t maternal ingestion of, effect on fetus and dysfibrinogenemia in, 2159
Hemoptysis, 5, 1987 newborn, 112 in erythropoietic protoporphyria, 898, 899
Hemorrhage. See Bleeding mechanism of action, 1919, 1919t, 1959 in hemochromatosis, 641–642, 643
Hemorrhagic fevers, 2086, 2207 for myocardial infarction, 2295–2296 hemostatic alterations in, 2191–2195
Hemosiderin, 42., 618, 633 for paroxysmal nocturnal hemoglobinuria in acute liver failure, 2193
Hemosiderosis, 639 during pregnancy, 580 changes contributing to bleeding/
Hemostasis. See also under Coagulation pharmacology of, 396 thrombosis, 2192, 2193t
disorders. See also Platelets, disorders platelet factor 4 and, 1844, 2026–2028, fibrinolysis, 2192
in acute promyelocytic leukemia, 1405 2026f, 2027f during liver transplantation, 2193
bleeding history, 1985–1986 platelet function and, 2078 management, 2193–2194
classification, 1985, 1986t resistance to, 397 primary hemostasis, 2191
clinical manifestations, 1987–1988, reversal of therapy, 397 secondary hemostasis, 2192
1987t for unstable angina, 2296 in Langerhans cell histiocytosis, 1104, 1106
evaluation/diagnosis, 1988–1989, 1989f, for venous thromboembolism, 2273–2274 in mastocytosis, 974
2040–2042, 2041f for venous thromboembolism prophylaxis multipotential cell therapy for, 452
iron deficiency in, 629 during pregnancy, 123 platelet dysfunction in, 2086
laboratory features, 1990–1991 Heparin-binding protein (azurocidin), 1012t, vs. primary myelofibrosis, 1327
physical examination, 1988 1013 in sickle cell disease, 772
preoperative assessment of, 1990, 1990t Heparin cofactor II, 1952t, 1960 thrombocytopenia and, 2013
inflammatory mediators in, 1979t Heparin-induced osteoporosis, 2277 thrombosis in, 2194–2195
pathways. See Coagulation, pathways; Heparin-induced thrombocytopenia (HIT), Hepatic endoplasmic reticulum retention,
Coagulation factors 2025–2032 2155
platelet function in, 2039 clinical features, 2028–2029, 2029t Hepatic hematopoiesis, 100–101
vascular function in, 1967–1979 complications, 396, 2277 Hepatic porphyrias, 889. See also Porphyria
adhesion molecules, 1976 differential diagnosis, 2029, 2031 cutanea tarda (PCT)
eicosanoid pathway, 1969–1970 epidemiology, 2025, 2277 Hepatic stem/progenitor cells, 452

Kaushansky_index_p2393-2506.indd 2443 9/21/15 3:22 PM